Last reviewed · How we verify
Control IPV
Control IPV is an inactivated poliovirus vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3.
Control IPV is an inactivated poliovirus vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3. Used for Poliomyelitis prevention in infants and children.
At a glance
| Generic name | Control IPV |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | Inactivated viral vaccine |
| Target | Poliovirus antigens (types 1, 2, 3) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains chemically inactivated (killed) poliovirus particles that cannot cause disease but trigger a protective immune response. Upon administration, the immune system recognizes these viral antigens and generates neutralizing antibodies and cellular immunity against poliovirus. This immunity prevents infection and disease if the vaccinated individual is exposed to wild-type poliovirus.
Approved indications
- Poliomyelitis prevention in infants and children
Common side effects
- Injection site pain or swelling
- Fever
- Irritability or fussiness
Key clinical trials
- Long-term Use of Intrapulmonary Percussive Ventilation for Preventing Hospitalizations Due to Respiratory Decompensation in Children With Multiple Disabilities (NA)
- Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine (PHASE4)
- Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mechanical Ventilation (NA)
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- RISE With Veteran Service Providers (NA)
- Developing and Testing the Jenga Dada Intervention in Kenya (NA)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- What Works - Malawi SASA! Together (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Control IPV CI brief — competitive landscape report
- Control IPV updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI